

Technology Appraisal Committee Meeting (Committee A)
10 Spring Gardens, London SW1A 2BU

Minutes: Confirmed

Date and Time: Tuesday 18 September 2018, 10:00 – 17:00

Present:	1. Dr Jane Adam (Chair) 2. Professor Iain Squire (Vice-Chair) 3. Dr Steve Edwards 4. Dr Rita Faria 5. Mr Adrian Griffin 6. Ms Pamela Rees 7. Dr Brian Shine 8. Dr John Watkins 9. Min Ven Teo 10. Dr Paul Robinson 11. Dr Justin Daniels 12. Professor John McMurray 13. Sumithra Maheswaran 14. Nigel Westwood 15. David Chandler	Present for all notes Present for notes 1 to 6 and 12 to 21 Present for all notes Present for all notes Present for all notes Present for all notes Present for all notes
-----------------	--	---

In attendance:

Helen Knight	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Jasdeep Hayre	Associate Director, National Institute for Health and Care Excellence	Present for notes 7 to 11
Thomas Feist	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Gemma Barnacle	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Marcela Haasova	Technical Analyst, National Institute for	Present for notes 1 to 6

	Health and Care Excellence	
Joanna Richardson	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 1 to 6 and 12 to 16
Emily Eaton Turner	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 7 to 11
Victoria Kelly	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 7 to 11
Boglarka Mikudina	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 12 to 16
Eleanor Donegan	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 17 to 21
Sana Khan	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 17 to 21
Jonathan Shepherd	SHTAC, Evidence Review Group	Present for notes 1 to 3
Jo Lord	SHTAC, Evidence Review Group	Present for notes 1 to 3
Janette Greenhalgh	LRiG, Evidence Review Group	Present for notes 7 to 8
James Mahon	LRiG, Evidence Review Group	Present for notes 7 to 8
Daniel Pollard	ScHARR, Evidence Review Group	Present for notes 12 to 13
Irina Tikhonova	PenTAG, Evidence Review Group	Present for notes 17 to 18
Dr Andreas Makris	Clinical expert	Present for notes 1 to 3
Dr Sophie Papa	Clinical expert	Present for notes 7 to 8
Ms Delia Sworm	Clinical expert	Present for notes 7 to 8

Dr Tariq Iqbal	Clinical expert	Present for notes 12 to 13
Dr Shuaib Nasser	Clinical expert	Present for notes 17 to 18
Dr Adel Mansur	Clinical expert	Present for notes 17 to 18
Holly Heath	Patient expert	Present for notes 1 to 3
Paula Carr	Patient expert	Present for notes 12 to 13
Damian McCluskey	Patient expert	Present for notes 12 to 13
Professor Peter Clark	Cancer Drugs Fund Clinical Lead	Present for notes 1 to 11

Non-public attendees:

Ana Uribe Echeverry	Corporate Office Coordinator, NICE	Present for all notes
Adam Storrow	Business Analyst, NICE	Present for all notes
Ria Skelton	Editor, NICE	Present for all notes
Chloe Kastoryano	Public Involvement Adviser, NICE	Present for notes 1 to 16
Thomas Strong	Cancer Drugs Fund, NICE	Present for notes 7 to 11
Hamish Lunagaria	Scientific Advice, NICE	Present for notes 1 to 6
Lulieth Torres	Technology Appraisals, NICE	Present for notes 1 to 11
Sarada Chunduri- Shoesmith	Health and Social Care, NICE	Present for all notes
Adam Jellett	Academy of Medical Sciences	Present for notes 1 to 6

Notes

Any other business

1. None.

Appraisal of abemaciclib with an aromatase inhibitor for untreated advanced hormone-receptor positive, HER2-negative breast cancer [ID1227]

Part 1 – Open session

2. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Eli Lilly and Company.
3. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.
 - 3.1. Dr Andreas Makris declared that he has been invited to an advisory board by Eli Lilly. This has not yet taken place.
 - 3.1.1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
 - 3.2. No further conflicts of interest were declared for this appraisal.

Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)

4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
5. The committee decision was based on consensus.
6. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of pembrolizumab for adjuvant treatment of melanoma with high risk of recurrence [ID1266]

Part 1 – Open session

7. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from MSD.

8. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests

8.1. Dr Sophie Papa declared an interest as she has received travel and accommodation expenses from MSD for attending conferences.

8.1.1. It was agreed that this declaration would not prevent them from participating in this section of the meeting.

8.2. Paul Robinson declared that his employer is the company for this appraisal and therefore did not take part in this appraisal discussion.

8.3. No further conflicts of interest were declared for this appraisal.

Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)

9. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.

10. The committee decision was based on consensus.

11. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of darvadstrocel for treating perianal fistula in Crohn's disease [ID960]

Part 1 – Open session

12. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Takeda UK.

13. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests

13.1. No conflicts of interest were declared for this appraisal.

Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)

14. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.

15. The committee decision was based on consensus.
16. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of benralizumab for treating severe eosinophilic asthma [ID1129]

Part 1 – Open session

17. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from AstraZeneca.
18. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests
 - 18.1. Dr Shuaib Nasser declared a direct financial interest as he has received payments for advisory boards for GSK, TEVA and Novartis. He has undertaken clinical trials for GSK on mepolizumab, AstraZeneca for benralizumab, and Novartis.
 - 18.1.1. It was agreed that this declaration would not prevent them from participating in this section of the meeting.
 - 18.2. Dr Adel Mansur declared a direct financial interest as he has received payments for advisory boards, talks, educational programmes, and sponsorship for conferences for pharmaceutical companies including AstraZeneca, GSK, Novartis, NAPP, BI, TEVA and Chiesi.
 - 18.2.1. It was agreed that this declaration would not prevent them from participating in this section of the meeting.
 - 18.3. John McMurray declared an indirect interest as his employer has received funding from AstraZeneca for a trial in heart failure.
 - 18.3.1. It was agreed that this declaration would not prevent them from participating in this section of the meeting.
 - 18.4. No further conflicts of interest were declared for this appraisal.

Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)

19. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
20. The committee decision was based on consensus.

21. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.